Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men’s health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, announce the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and delivering value to patients, partners, and investors.
Read the full article: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement //
Source: https://www.globenewswire.com/news-release/2025/09/26/3156997/0/en/Joint-Press-Release-Onconetix-and-Ocuvex-Announce-Mutual-Termination-of-Merger-Agreement.html